Categories
Jump to navigation
Jump to search
The following categories exist on the wiki, and may or may not be unused. Also see wanted categories.
(first | last) View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)- 5 alpha-reductase inhibitors (2 members)
- ACVR1 inhibitors (1 member)
- AKT1 inhibitors (4 members)
- ALK inhibitors (9 members)
- AXL inhibitors (2 members)
- AbbVie product (1 member)
- Acid pump antagonists (1 member)
- Acquired coagulopathy medications (2 members)
- Acquired coagulopathy regimens (1 member)
- Acquired hemophilia A medications (7 members)
- Acquired hemophilia A regimens (1 member)
- Acquired thrombotic thrombocytopenic purpura medications (7 members)
- Acquired thrombotic thrombocytopenic purpura regimens (1 member)
- Acute leukemias (15 members)
- Acute lymphoblastic leukemia, infant medications (4 members)
- Acute lymphoblastic leukemia, infant regimens (2 members)
- Acute lymphoblastic leukemia medications (1 member)
- Acute lymphoblastic leukemia regimens (3 members)
- Acute lymphoblastic leukemias (10 members)
- Acute myeloid leukemia medications (40 members)
- Acute myeloid leukemia medications (historic) (11 members)
- Acute myeloid leukemia medications (investigational) (10 members)
- Acute myeloid leukemia regimens (9 members)
- Acute promyelocytic leukemia medications (16 members)
- Acute promyelocytic leukemia regimens (2 members)
- Adrenal suppressant (1 member)
- Adrenergic receptor agonists (1 member)
- Adrenocortical carcinoma medications (6 members)
- Adrenocortical carcinoma medications (investigational) (1 member)
- Adrenocortical carcinoma regimens (2 members)
- Adult T-cell leukemia-lymphoma medications (17 members)
- Adult T-cell leukemia-lymphoma regimens (2 members)
- Adult T-cell leukemia/lymphoma medications (0 members)
- Adult T-cell leukemia/lymphoma regimens (0 members)
- Aggressive lymphomas (7 members)
- Aggressive non-Hodgkin lymphomas (11 members)
- Alkalinization (1 member)
- Alkyl sulfonates (1 member)
- Alkylating agents (34 members)
- Allogeneic HSCT regimens (1 member)
- Alloimmune hematologic conditions (1 member)
- Alpha emitters (1 member)
- Alveolar soft part sarcoma medications (1 member)
- Alveolar soft part sarcoma regimens (1 member)
- Aminopeptidase inhibitor (1 member)
- Anabolic steroids (2 members)
- Anal cancer medications (11 members)
- Anal cancer regimens (1 member)
- Anaplastic glioma medications (16 members)
- Anaplastic glioma regimens (2 members)
- Anaplastic large cell lymphoma, pediatric medications (1 member)
- Anaplastic large cell lymphoma medications (14 members)
- Anaplastic large cell lymphoma regimens (2 members)
- Androgen receptor inhibitors (1 member)
- Angiosarcoma medications (3 members)
- Angiosarcoma regimens (1 member)
- Anthracenedione (1 member)
- Anthracyclines (12 members)
- Anti-BCMA-CD3 bispecific antibodies (2 members)
- Anti-BCMA/CD3 bispecific antibodies (0 members)
- Anti-BCMA CAR T-cells (2 members)
- Anti-BCMA antibodies (1 member)
- Anti-BCMA antibody-drug conjugates (1 member)
- Anti-BCMA bispecific T-cell engager antibodies (0 members)
- Anti-BCMA cellular therapy (2 members)
- Anti-C1s antibodies (1 member)
- Anti-C5 antibodies (4 members)
- Anti-CCR4 antibodies (1 member)
- Anti-CD137 cellular therapy (4 members)
- Anti-CD19-CD3 bispecific antibodies (1 member)
- Anti-CD194 antibodies (1 member)
- Anti-CD19 BiTE antibodies (0 members)
- Anti-CD19 CAR T-cells (4 members)
- Anti-CD19 antibodies (2 members)
- Anti-CD19 antibody-drug conjugates (3 members)
- Anti-CD19 bispecific T-cell engager antibodies (0 members)
- Anti-CD19 cellular therapy (4 members)
- Anti-CD20-CD3 bispecific antibodies (3 members)
- Anti-CD20 BiTE antibodies (0 members)
- Anti-CD20 antibodies (14 members)
- Anti-CD20 bispecific T-cell engager antibodies (0 members)
- Anti-CD20 cellular therapy (0 members)
- Anti-CD20 radioimmunoconjugates (2 members)
- Anti-CD22 antibodies (3 members)
- Anti-CD22 antibody-drug conjugates (1 member)
- Anti-CD22 immunotoxins (2 members)
- Anti-CD27 antibodies (1 member)
- Anti-CD28 cellular therapy (2 members)
- Anti-CD30 antibodies (1 member)
- Anti-CD30 antibody-drug conjugates (1 member)
- Anti-CD33-CD3 bispecific antibodies (1 member)
- Anti-CD33/CD3 bispecific antibodies (0 members)
- Anti-CD33 antibodies (2 members)
- Anti-CD33 antibody-drug conjugates (2 members)
- Anti-CD33 bispecific T-cell engager antibodies (0 members)
- Anti-CD33 radioimmunoconjugates (1 member)
- Anti-CD37 antibodies (1 member)
- Anti-CD37 medications (0 members)
- Anti-CD38 antibodies (5 members)
- Anti-CD3 antibodies (0 members)
- Anti-CD3 cellular therapy (4 members)
- Anti-CD47 antibodies (1 member)
- Anti-CD52 antibodies (1 member)
- Anti-CD79B antibodies (1 member)
- Anti-CD79B antibody-drug conjugates (1 member)
- Anti-CD7 CAR T-cells (1 member)
- Anti-CLDN18.2 antibodies (1 member)
- Anti-CTLA-4 antibodies (2 members)
- Anti-DKK1 antibodies (1 member)
- Anti-DLL3-CD3 bispecific antibodies (1 member)
- Anti-EGFR-HGFR bispecific antibodies (1 member)
- Anti-EGFR/HGFR bispecific antibodies (0 members)
- Anti-EGFR antibodies (3 members)
- Anti-EGFRvIII CAR T-cells (2 members)
- Anti-EpCAM-CD3 bispecific antibodies (1 member)
- Anti-EpCAM BiTE antibodies (0 members)
- Anti-EpCAM antibodies (1 member)
- Anti-EpCAM bispecific T-cell engager antibodies (0 members)
- Anti-FOLR1 antibodies (1 member)
- Anti-FOLR1 antibody-drug conjugates (1 member)
- Anti-Factor IXa-Factor Xa bispecific antibodies (1 member)
- Anti-Factor IXa antibodies (0 members)
- Anti-Factor XIa antibodies (1 member)
- Anti-Factor Xa antibodies (0 members)
- Anti-GD2 CAR T-cells (1 member)
- Anti-GD2 antibodies (3 members)
- Anti-GD2 cellular therapy (1 member)
- Anti-GP-3 antibodies (1 member)
- Anti-GPIIb-IIIa antibodies (1 member)
- Anti-GPRC5D-CD3 bispecific antibodies (1 member)
- Anti-GPRC5D/CD3 bispecific antibodies (0 members)
- Anti-GPRC5D CAR T-cells (1 member)
- Anti-GPRC5D antibodies (0 members)
- Anti-GPRC5D bispecific T-cell engager antibodies (0 members)
- Anti-GPRC5D cellular therapy (1 member)
- Anti-HER2 antibodies (13 members)
- Anti-HER2 antibody-drug conjugates (2 members)
- Anti-HGFR antibodies (0 members)
- Anti-HGF antibodies (1 member)
- Anti-IFNg antibodies (1 member)
- Anti-IGF-1R antibodies (3 members)
- Anti-IL-2R immunotoxins (1 member)
- Anti-IL-5 antibodies (2 members)
- Anti-IL-6R antibodies (1 member)
- Anti-IL-6 antibodies (1 member)
- Anti-IL3 immunotoxins (0 members)
- Anti-KIR antibodies (1 member)
- Anti-LAG-3 antibodies (1 member)
- Anti-MAGE-A4 SPEAR T-cells (1 member)
- Anti-NGcGM3 antibodies (1 member)
- Anti-P-selectin antibodies (1 member)
- Anti-PD-1 antibodies (14 members)
- Anti-PD-L1 antibodies (6 members)
- Anti-PDGFR antibodies (1 member)
- Anti-PS antibodies (1 member)
- Anti-RANKL antibodies (1 member)
- Anti-SLAMF7 antibodies (1 member)
- Anti-TACSTD2 antibodies (1 member)
- Anti-TACSTD2 antibody-drug conjugates (1 member)
- Anti-TFPI antibodies (1 member)
- Anti-TF antibodies (1 member)
- Anti-TF antibody-drug conjugates (1 member)
- Anti-TRAIL-R1 antibodies (1 member)
- Anti-TRAIL-R2 antibodies (1 member)
- Anti-VEGFR antibodies (1 member)
- Anti-VEGF antibodies (8 members)
- Anti-amyloid antibodies (1 member)
- Anti-c-Met antibodies (1 member)
- Anti-dabigatran antibody fragments (1 member)
- Anti-diarrheals (1 member)
- Anti-mesothelin antibodies (1 member)
- Anti-nectin-4 antibodies (1 member)
- Anti-nectin-4 antibody-drug conjugates (1 member)
- Anti-vWF medications (1 member)
- Antiandrogens (7 members)
- Antibacterials (10 members)
- Antibiotics (4 members)
- Antibody-drug conjugates (11 members)
- Antibody medications (6 members)
- Anticoagulant reversal agents (2 members)
- Anticoagulants (20 members)
- Anticoagulation factors (1 member)
- Antiestrogens (4 members)
- Antifolates (8 members)
- Antifungals (7 members)
- Antihelminthic (1 member)
- Antihistamines (8 members)
- Antileukotrienes (1 member)
- Antimetabolites (25 members)
- Antineoplastic bispecific antibodies (1 member)
- Antineoplastic monoclonal antibodies (41 members)
- Antineoplastics by class effect (5 members)
- Antiparasitic (1 member)
- Antiphospholipid antibody syndrome medications (2 members)
- Antiphospholipid antibody syndrome regimens (1 member)
- Antiplatelet agents (5 members)
- Antipsychotic (2 members)
- Antipyretics (5 members)
- Antithymocyte globulin (3 members)
- Antitumor antibiotics (7 members)
- Antivirals (4 members)
- Aplastic anemia medications (7 members)
- Aplastic anemia regimens (1 member)
- Apoptosis promoters (2 members)
- Appendiceal tumor regimens (1 member)
- Appetite stimulants (2 members)
- Approved drugs (6 members)
- Aromatase inhibitors (3 members)
- Aromatase inhibitors, first generation (1 member)
- Aromatase inhibitors, second generation (2 members)
- Aromatase inhibitors, third generation (3 members)
- Arsenic compound (3 members)
- Asparagine-specific enzymes (5 members)
- AstraZeneca product (2 members)
- Atypical hemolytic uremic syndrome medications (4 members)
- Atypical hemolytic uremic syndrome regimens (1 member)
- Aurora kinase inhibitors (2 members)
- Autoimmune cytopenia medications (2 members)
- Autoimmune cytopenia regimens (1 member)
- Autoimmune hematologic conditions (7 members)
- Autoimmune hemolytic anemia regimens (0 members)
- Autologous HSCT regimens (1 member)
- B-cell acute lymphoblastic leukemia medications (42 members)
- B-cell acute lymphoblastic leukemia medications (historic) (4 members)
- B-cell acute lymphoblastic leukemia medications (investigational) (1 member)
- B-cell acute lymphoblastic leukemia regimens (6 members)
- B-cell lymphoma medications (6 members)
- B-cell lymphoma regimens (11 members)
- B-cell lymphomas (18 members)
- BRAF inhibitors (7 members)
- BRAF medications (0 members)
- BRAF regimens (0 members)
- BTK inhibitors (8 members)
- Bcl-2 inhibitors (1 member)
- Bcl-2 translation inhibitors (1 member)
- Bcr-Abl inhibitors (9 members)
- Benzodiazepine (3 members)
- Beta emitters (1 member)
- Beta thalassemia medications (2 members)
- Beta thalassemia regimens (1 member)
- Biliary tract cancer regimens (0 members)
- Biliary tract cancers (5 members)
- Biologic products (3 members)
- Biomarker-specific medications (2 members)
- Biomarker-specific pages (53 members)
- Biosimilars (33 members)
- Bispecific antibody medications (3 members)
- Bisphosphonates (6 members)
- Bladder cancer medications (21 members)
- Bladder cancer medications (historic) (0 members)